Biotech
A Two-Target Cancer Drug Just Cut Lung-Cancer Progression Risk by 60%
A Phase 3 trial of iza-bren nearly doubled progression-free survival in EGFR-mutated lung cancer: 11.1 vs 5.7 months, cutting progression risk 60%.
Topic
Cancer
The latest Cancer news and analysis from Tech Arcade.